Although the differential response rates to erlotinib in this study are intriguing and further consolidate the heterogeneity of MMTV-Wnt1-driven mammary tumors, the immediate translational significance of this observation for human triple-negative breast cancer (TNBC) patients is unknown. The gene discussed is WNT1; the disease is triple-negative breast carcinoma.